Nektar Therapeutics
455 Mission Bay Blvd South
San Francisco
California
94158
United States
Tel: 415-482-5300
Website: http://www.nektar.com/
Email: iaffairs@nektar.com
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer and auto-immune disease. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates. Our success is rooted in four key elements: our track record reflected by a portfolio of successful approved medicines which emanated from our chemistry platform and are made available globally by our pharmaceutical partners, our unique research and development pipeline of new investigational medicines in cancer and immunology, our proprietary and proven science and technology approach that fuels our discovery efforts and our team of dedicated scientists, clinicians and employees focused on bringing new medicines to patients with debilitating diseases.
Stock Symbol: NKTR
Stock Exchange: NASDAQ
484 articles about Nektar Therapeutics
-
Nektar Therapeutics (CA)' President and CEO, Howard W. Robin, to Present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA
1/4/2013
-
AstraZeneca PLC, Nektar Therapeutics (CA) Opioid Constipation Drug May Have Failed Phase III Study
11/14/2012
-
Nektar Therapeutics (CA) to Host Conference Call to Discuss The Positive Phase 3 Clinical Results for Naloxegol
11/12/2012
-
Nektar Therapeutics (CA) to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
11/7/2012
-
Nektar Therapeutics (CA) Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11/7/2012
-
Nektar Therapeutics (CA) Presents Positive Preclinical Data for NKTR-171, a Novel Sodium Channel Blocker to Treat Neuropathic Pain, at 41st Annual Meeting of the Society For Neuroscience
10/15/2012
-
Nektar Therapeutics (CA) Release: NKTR-192, A New Short-Acting Mu-Opioid Analgesic Molecule, Achieves Desired Pharmacokinetic Profile in First Phase 1a Clinical Study
9/18/2012
-
Nektar Therapeutics (CA)' President and CEO, Howard W. Robin, to Present at the UBS 2012 Global Life Sciences Conference in New York City
9/13/2012
-
Nektar Therapeutics (CA) Reports Financial Results for the Second Quarter of 2012
8/10/2012
-
Nektar Therapeutics (CA) Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
8/7/2012
-
Nektar Therapeutics (CA) to Announce Financial Results for the Second Quarter of 2012 On Thursday, August 9, 2012, After Close of U.S.-Based Financial Markets
8/3/2012
-
Nektar Therapeutics (CA) Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
7/24/2012
-
Nektar Therapeutics (CA) Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7/10/2012
-
Nektar Therapeutics (CA) Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
6/7/2012
-
Nektar Therapeutics (CA)' President and CEO Howard W. Robin to Present at the Jefferies and Co. 2012 Global Healthcare Conference in New York
5/31/2012
-
Nektar Therapeutics (CA) to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
4/25/2012
-
Nektar Therapeutics (CA) to Host Investor and Analyst R&D Day in New York City
4/10/2012
-
Nektar Therapeutics (CA) Doses First Subjects in Phase 1 Clinical Study Evaluating NKTR-192, a New Short-Acting Opioid Molecule for the Treatment of Acute Pain
4/2/2012
-
Affymax, Inc., MAP Pharmaceuticals, Inc. Drug Approvals Would Net Royalty Bounty for Nektar Therapeutics (CA)
3/26/2012
-
Nektar Therapeutics (CA) Moving 30 Research Jobs to SF
3/20/2012